Bergen, 16 April 2007; The board has pursuant to the subscriptions received during the subscription period of the rights issue, resolved to issue the maximum number of shares in the offering, i.e. 1,176,470 shares, shall be issued at a subscription price of NOK 8.50 per share according to the board resolution of 20 March 2007.

The company`s share capital will following this be NOK 3,832,381.50, divided on 38,323,815 shares, each of a nominal value of NOK 0.10.

A notice of allotment will be sent to the subscribers 16 April 2007.

Together with the private placement concluded in March, the Company now has received NOK 42.6 million in new equity.

- The new equity gives us necessary strength to develop the Company`s positions in gene based diagnostics of cancer and infectious diseases - says CEO Mårten Wigstøl. NorDiag acquired Genpoint AS earlier this year and increased its intellectual resources and properties substantially.

Contactperson: CEO Mårten Wigstøl, mob. 911 657 75

About NorDiag ASA
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed on Oslo Stock Exchange with ticker NORD.